Comprehensive Overview on Antibody Drug Conjugates- A Promising Approach in Cancer Therapy
Abstract
Chemotherapy remains a cornerstone in cancer treatment, utilizing cytotoxic agents to kill or inhibit the growth of cancer cells. However, its efficacy is often limited by systemic toxicity and the development of resistance. To address these challenges, Antibody-Drug Conjugates (ADCs) have emerged as a promising therapeutic strategy, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. ADCs are designed to deliver targeted chemotherapy directly to cancer cells, reducing off-target effects and improving therapeutic outcomes. The structure of ADCs consists of a monoclonal antibody, a cytotoxic agent (payload), and a chemical linker. The antibody specifically binds to tumor-associated antigens, facilitating internalization of the drug, which is then released within the cancer cell to induce cell death. This selective targeting minimizes the damage to normal, healthy tissues. Since the first ADC approval in 2000, the field has rapidly advanced, with multiple ADCs receiving FDA approval for both hematological and solid tumors. Despite their potential, ADC development faces challenges such as linker stability, payload delivery, and tumor penetration. Recent advancements have led to the development of second and third-generation ADCs, which feature improved stability, efficacy, and safety profiles. The future of ADCs lies in optimizing their design, including selecting appropriate antigens, refining drug-to-antibody ratios, and enhancing intracellular delivery mechanisms. Overall, ADCs represent a transformative approach to cancer therapy, offering a more targeted, effective, and safer treatment option for cancer patients.
Keywords: ADC, Cancer, Chemotherapy, Cytotoxic drug, Carrier, Linker, Target therapy, Toxicity.
Keywords:
chemotherapy, ADC, Cancer, Cytotoxic drug, Carrier, Linker, Target therapy, ToxicityDOI
https://doi.org/10.22270/jddt.v15i3.7011References
1. What is cancer? National Cancer Institute. 2021. Available at: https://www.cancer.gov/about-cancer/understanding/what-is-cancer. Accessed December 24, 2024.
2. Cancer 2022.Who.int. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
3. Nygren P. What is cancer chemotherapy? Acta Oncologica. 2001 Jan 1; 40(2-3):166-74. https://doi.org/10.1080/02841860151116204 PMid:11441929
4. Ziad Abuhelwa. A Comprehensive review on Antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). CANCER TREATMENT REVIEWS. 2022 May; 106(102393). https://doi.org/10.1016/j.ctrv.2022.102393 PMid:35472631
5. Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-Drug Conjugates: A Comprehensive review. Molecular Cancer Research. 2019 Oct 28; 18(1):3-19. https://doi.org/10.1158/1541-7786.MCR-19-0582 PMid:31659006
6. Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein & Cell. 2016 Oct 14; 9(1):33-46. https://doi.org/10.1007/s13238-016-0323-0 PMid:27743348 PMCid:PMC5777969
7. Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-A new wave of cancer drugs. Bioorganic & Medicinal Chemistry Letters. 2014 Oct 13; 24(23):5357-63. https://doi.org/10.1016/j.bmcl.2014.10.021 PMid:25455482
8. Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020 Oct 16;25(20):4764. https://doi.org/10.3390/molecules25204764 PMid:33081383 PMCid:PMC7587605
9. Shastry M, Gupta A, Chandarlapaty S, Young M, Powles T, Hamilton E. Rise of Antibody-Drug Conjugates: The Present and Future. 2023 ASCO EDUCATIONAL BOOK. 2023. https://doi.org/10.1200/EDBK_390094 PMid:37229614
10. Joubert N 1, Beck A 2, Dumontet C 3, 4, Caroline Denevault-Sabourin. Antibody-Drug conjugates: The last decade. Vol. 13, Pharmaceuticals. 2020 Sep p. 245. https://doi.org/10.3390/ph13090245 PMid:32937862 PMCid:PMC7558467
11. Timeline: charting the choppy history of 'magic bullet' antibody-drug conjugates. Pharmaceutical Technology. 2021. Available from: https://www.pharmaceutical-technology.com/features/antibody-drug-conjugates-timeline/
12. Lambert JM, Berkenblit A, ImmunoGen, Inc. Antibody-Drug conjugates for cancer treatment. Annual Review of Medicine. 2018 p. 191-207. https://doi.org/10.1146/annurev-med-061516-121357 PMid:29414262
13. Lu J 1,2, Jiang F 1,2,3, Lu A 1,2, Zhang G 1,2. Linkers having a crucial role in Antibody-Drug conjugates. Wenbin Deng, editor. Vol. 17, International Journal of Molecular Sciences. 2016 Apr p. 561. https://doi.org/10.3390/ijms17040561 PMid:27089329 PMCid:PMC4849017
14. Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomarker Research. 2019 Oct 31; 7(1). https://doi.org/10.1186/s40364-019-0175-x PMid:31695916 PMCid:PMC6824118
15. Reis, J. C., et al. Chemical conjugation of drugs to antibodies: Current methods and future perspectives. Molecular Pharmacology. 2014 81(2), 201-211. DOI:10.1124/mol.113.088757.
16. Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst. Pharmacol. 2017 Jun. https://doi.org/10.1002/psp4.12224 PMid:28653357 PMCid:PMC5613179
17. Akkapeddi P, Azizi SA, Freedy AM, Cal PMSD, Gois PMP, Bernardes GJL. Construction of homogeneous antibody-drug conjugates using site-selective protein chemistry. Chemical Science. 2016 Jan 1; 7(5):2954-63. https://doi.org/10.1039/C6SC00170J PMid:29997785 PMCid:PMC6005007
18. Jackson DY. Processes for constructing homogeneous antibody drug conjugates. Organic Process Research & Development. 2016 Apr 14; 20(5):852-66. https://doi.org/10.1021/acs.oprd.6b00067
19. Deslandes A. Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. mAbs. 2014 Apr 24; 6(4):859-70. https://doi.org/10.4161/mabs.28965 PMid:24852950 PMCid:PMC4171021
20. Kim EG, Kim KM. Strategies and advancement in Antibody-Drug conjugate optimization for targeted cancer therapeutics. Biomolecules & Therapeutics. 2015 Oct 22; 23(6):493-509. https://doi.org/10.4062/biomolther.2015.116 PMid:26535074 PMCid:PMC4624065
21. Coulson A, Levy A, Gossell-Williams M. Monoclonal antibodies in cancer therapy: Mechanisms, successes and limitations. West Indian Medical Journal. 2014 Jan 1; https://doi.org/10.7727/wimj.2013.241 PMid:25803383 PMCid:PMC4663950
22. Sheyi R, De La Torre BG, Albericio F. Linkers: an assurance for controlled delivery of Antibody-Drug conjugate. Pharmaceutics. 2022 Feb 11; 14(2):396. https://doi.org/10.3390/pharmaceutics14020396 PMid:35214128 PMCid:PMC8874516
23. Kovacs E. Navigating the challenges and complexities of ADC development [Internet]. The Medicine Maker. 2024. Available from: https://themedicinemaker.com/discovery-development/navigating-the-challenges-and-complexities-of-adc-development
24. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduction and Targeted Therapy. 2022 Mar 22;7(1). https://doi.org/10.1038/s41392-022-00947-7 PMid:35318309 PMCid:PMC8941077
25. Ajinomoto Althea, Inc. 5 ADC Manufacturing Challenges You Need To Know. Pharmaceutical Online. 2016 Sep 13; Available from: https://www.pharmacompass.com/pdf/party/content/adcchallanges.pdf
26. Scanlan C. Antibody-Drug Conjugates: Manufacturing challenges and trends. ADC Review. 2019. Available from: https://www.adcreview.com/articles/antibody-drug-conjugates-manufacturing-challenges-trends/amp/
27. Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2021 Jan 1; 26(19):5847. https://doi.org/10.3390/molecules26195847 PMid:34641391 PMCid:PMC8510272
28. Liu K, Li M, Li Y, Li Y, Chen Z, Tang Y, et al. A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers. Molecular Cancer. 2024 Mar 23; 23(1). https://doi.org/10.1186/s12943-024-01963-7 PMid:38519953 PMCid:PMC10960395
29. Gogia P, Ashraf H, Bhasin S, Xu Y. Antibody-Drug Conjugates: A review of approved drugs and their clinical level of evidence. Cancers. 2023 Jul 30; 15(15):3886. https://doi.org/10.3390/cancers15153886 PMid:37568702 PMCid:PMC10417123
30. García-Alonso S, Ocaña A, Pandiella A. Resistance to Antibody-Drug conjugates. Cancer Research. 2018 Apr 13; 78(9):2159-65. https://doi.org/10.1158/0008-5472.CAN-17-3671 PMid:29653942
Published
Abstract Display: 678 
PDF Downloads: 1268 PDF Downloads: 84 How to Cite
Issue
Section
Copyright (c) 2025 Leena Muppa, Shruthi Ravindranathan, S Sivaram , Aadhira Jinnah, Achsa Sharon Shibu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.